Grant of options and PDMR dealing

Summary by AI BETAClose X

Arecor Therapeutics plc announced the grant of 455,000 Long Term Incentive Plan options over new ordinary shares at an exercise price of £0.01 each. These options were awarded to key personnel, including the CEO, CFO, CSO, and CDO, with vesting contingent on continued service and performance conditions over a three-year period, including outperformance against the FTSE AIM All Share index. The grant date was 20 May 2026, and the options are exercisable from after the three-year performance period until the tenth anniversary of the grant date, subject to a one-year holding period post-vesting.

Disclaimer*

UK 100

Latest directors dealings